Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)
NCT 04862663 Brief Summary A Phase Ib/III Open-label, Randomised Study of Capivasertib…
Read more arrow_forwardNCT 04862663 Brief Summary A Phase Ib/III Open-label, Randomised Study of Capivasertib…
Read more arrow_forwardNCT 05523947 Brief Summary This first-in-human study will be counducted to evaluate…
Read more arrow_forwardNCT 05868174 Brief Summary This is an open label, single-arm, multicentre dose…
Read more arrow_forwardNCT 05756907 Brief Summary This is a Phase 1b/2a, open-label, adaptive-design outpatient…
Read more arrow_forwardInside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.